Inhibition of hepatocellular carcinoma by fulvestrant involves the estrogen receptor α and Wnt pathways in vitro and in patients

Wang,Cong-Jun; Guo,De-Kai; You,Tian-Geng; Shen,Dong-Wei; Wang,Chao; Tang,Lin; Wang,Jian; Xu,Rong-Hua; Zhang,Hui

doi:10.3892/mmr.2014.2595

Inhibition of hepatocellular carcinoma by fulvestrant involves the estrogen receptor α and Wnt pathways in vitro and in patients

Authors:
- Cong-Jun Wang
- De-Kai Guo
- Tian-Geng You
- Dong-Wei Shen
- Chao Wang
- Lin Tang
- Jian Wang
- Rong-Hua Xu
- Hui Zhang
View Affiliations

Affiliations: Department of Hepatobiliary and Pancreatic Diseases, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China
Published online on: September 23, 2014 https://doi.org/10.3892/mmr.2014.2595
Pages: 3125-3131

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of anti-estrogen treatment (fulvestrant) on the biological activity of hepatocellular carcinoma (HCC), involving the estrogen receptor α (ERα) and Wnt pathways, and to evaluate whether ERα and Wnt inhibitory factor-1 (WIF1) could be biomarkers for anti-estrogen clinical therapy. H22 and HepG2 cells were treated with 0.04 to 625 nM fulvestrant and the WST-8 method was used to assess the inhibition rate after 72 h. Furthermore, prolactin (PRL) secretion by HepG2 cells was assessed at 24 h using an enzyme immunoassay. Quantitative polymerase chain reaction and western blot analysis were used to analyze the mRNA and protein expression levels of ERα, β-catenin and WIF1, respectively, in HepG2 cells. For clinical patient analysis, the tumor volume was analyzed by magnetic resonance imaging methods, and PRL in the blood was detected by an enzyme immunoassay. In HepG2 cells, the mRNA and protein expression levels of ERα were downregulated (P<0.01), while β-catenin expression remained unchanged and WIF1 expression was upregulated (P<0.01). Analysis of samples from clinical patients demonstrated that there was a positive correlation between PRL levels and tumor volume. In addition, as compared with non-cancerous tissues, the ERα mRNA levels in tumor tissue were upregulated (P<0.05), particularly in that of male patients, while WIF1 expression was significantly downregulated (P<0.01). In conclusion, fulvestrant inhibited the proliferation of HepG2 cells, involving the ERα and non-canonical Wnt pathways, and it may be a promising therapeutic for HCC.

View Figures

View References

1	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
2	El-Serag HB: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 127:S27–S34. 2004. View Article : Google Scholar : PubMed/NCBI
3	Bosch FX, Ribes J, Díaz M and Cléries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology. 127:S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
4	Boonyaratanakornkit V and Edwards DP: Receptor mechanisms mediating non-genomic actions of sex steroids. Semin Reprod Med. 25:139–153. 2007. View Article : Google Scholar : PubMed/NCBI
5	Coe JE, Ishak KG and Ross MJ: Estrogen induction of hepatocellular carcinomas in Armenian hamsters. Hepatology. 11:570–577. 1990. View Article : Google Scholar : PubMed/NCBI
6	Giguère V: To ERR in the estrogen pathway. Trends Endocrinol Metab. 13:220–225. 2002.
7	Bunone G, Briand PA, Miksicek R and Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15:2174–2183. 1996.PubMed/NCBI
8	Pietras RJ, Arboleda J, Reese DM, et al: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 10:2435–2446. 1995.PubMed/NCBI
9	Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R and Grohe C: Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem. 275:18447–18453. 2000. View Article : Google Scholar : PubMed/NCBI
10	Liedert A, Wagner L, Seefried L, Ebert R, Jakob F and Ignatius A: Estrogen receptor and Wnt signaling interact to regulate early gene expression in response to mechanical strain in osteoblastic cells. Biochem Biophys Res Commun. 394:755–759. 2010. View Article : Google Scholar
11	Klaus A and Birchmeier W: Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 8:387–398. 2008. View Article : Google Scholar : PubMed/NCBI
12	Grumolato L, Liu G, Mong P, et al: Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev. 24:2517–2530. 2010. View Article : Google Scholar : PubMed/NCBI
13	Ingle JN, Suman VJ, Rowland KM, et al: Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol. 24:1052–1056. 2006. View Article : Google Scholar
14	Dang VH, Nguyen TH, Lee GS, Choi KC and Jeung EB: In vitro exposure to xenoestrogens induces growth hormone transcription and release via estrogen receptor-dependent pathways in rat pituitary GH3 cells. Steroids. 74:707–714. 2009. View Article : Google Scholar
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2[−Delta Delta C(T)]. Method. 25:402–408. 2001.
16	Carlsson G, Gullberg B and Hafström L: Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol. 105:20–23. 1983.PubMed/NCBI
17	Boutin JM, Edery M, Shirota M, et al: Identification of a cDNA encoding a long form of prolactin receptor in human hepatoma and breast cancer cells. Mol Endocrinol. 3:1455–1461. 1989. View Article : Google Scholar : PubMed/NCBI
18	Chamness GC, Costlow ME and McGuire WL: Estrogen receptor in rat liver and its dependence on prolactin. Steroids. 26:363–371. 1975. View Article : Google Scholar : PubMed/NCBI
19	Yue W, Wang JP, Li Y, et al: Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms. Int J Cancer. 127:1748–1757. 2010. View Article : Google Scholar : PubMed/NCBI
20	Fan M, Yan PS, Hartman-Frey C, et al: Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 66:11954–11966. 2006. View Article : Google Scholar : PubMed/NCBI
21	Zhai Y, Zhou G, Deng G, et al: Estrogen receptor alpha polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. Gastroenterology. 130:2001–2009. 2006. View Article : Google Scholar
22	Polakis P: Wnt signaling and cancer. Genes Dev. 14:1837–1851. 2000.
23	Ding Z, Qian YB, Zhu LX and Xiong QR: Promoter methylation and mRNA expression of DKK-3 and WIF-1 in hepatocellular carcinoma. World J Gastroenterol. 15:2595–2601. 2009. View Article : Google Scholar : PubMed/NCBI
24	Wu D, Wong P, Li W, Vogel CF and Matsumura F: Suppression of WIF-1 through promoter hypermethylation causes accelerated proliferation of the aryl hydrocarbon receptor (AHR) overexpressing MCF10AT1 breast cancer cells. Toxicology. 285:97–103. 2011. View Article : Google Scholar
25	van der Lely AJ, Harris AG and Lamberts S: The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol (Oxf). 37:181–185. 1992.PubMed/NCBI
26	Ohnishi S, Murakami T, Moriyama T, Mitamura K and Imawari M: Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue. Hepatology. 6:440–443. 1986. View Article : Google Scholar : PubMed/NCBI
27	Deng Y, Yu B, Cheng Q, et al: Epigenetic silencing of WIF-1 in hepatocellular carcinomas. J Cancer Res Clin Oncol. 136:1161–1167. 2010. View Article : Google Scholar : PubMed/NCBI